Abstract
Norfloxacin (NFLX), a new quinolone antibacterial agent, was investigated for its antibacterial activity and clinical efficacy on respiratory tract infections.
The results obtained are summarized as follows:
1. Antibacterial activities were evaluated against 127 strains of various bacteria isolated from clinical sources. MIC80's of this drug were: against Staphylococcus aureus and Streptococcus pyogenes 1.56μg/ml; Haemophilus influenzae 0.05μg/ml or less; and Klebsiella sp. and Enterobacter sp. 0.10μg/ml. These antibacterial activities were superior to these of ampicillin and cephalexin, except against S. pyogenes.
2. Clinical responses to NFLX in a total of 32 cases with respiratory tract infections were excellent in 9 cases, good in 12, fair in 9, poor in 2, with an efficacy rate of 65.6%.
Neither adverse reactions nor abnormalities of laboratory test results were observed.
